CoChat

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Open access
Hamlett, Eric D., Ledreux, Aurélie, Potter, Huntington, Chial, Heidi J., Patterson, David, Espinosa, Joaquin M., Bettcher, Brianne M., Granholm, Ann-Charlotte · 2018 · Free Radical Biology and Medicine
Cited by 76

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Every person with Down syndrome (DS) has the characteristic features of Alzheimer's disease (AD) neuropathology in their brain by the age of forty, and most go on to develop AD dementia. Since people with DS show highly variable levels of baseline function, it is often difficult to identify early signs of dementia in this population. The discovery of blood biomarkers predictive of dementia onset and/or progression in DS is critical for developing effective clinical diagnostics. Our recent studies show that neuron‐derived exosomes, which are small extracellular vesicles secreted by most cells in the body, contain elevated levels of amyloid‐beta peptides and phosphorylated‐Tau that could indicate a preclinical AD phase in people with DS starting in childhood. We also found that the relative levels of these biomarkers were altered following dementia onset. Exosome release and signaling are dependent on cellular redox homeostasis as well as on inflammatory processes, and exosomes may be involved in the immune response, suggesting a dual role as both triggers of inflammation in the brain and propagators of inflammatory signals between brain regions. Based on recently reported connections between inflammatory processes and exosome release, the elevated neuroinflammatory state observed in people with DS may affect exosomal AD biomarkers. Herein, we discuss findings from studies of people with DS, people with DS and AD (DS‐AD), and mouse models of DS showing new connections between neuroinflammatory pathways, oxidative stress, exosomes, and exosome‐mediated signaling, which may inform future AD diagnostics, preventions, and treatments in the DS population as well as in the general population. HIGHLIGHTSExosome technology can detect AD biomarkers decades prior to the onset of symptoms.Exosome signaling and release are affected by both oxidative homeostasis and inflammation.Exosomes may deliver therapies targeting oxidative stress, inflammation, and brain pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.freeradbiomed.2017.08.028

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 76

Metadata

Authors
Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A.-C.
Venue
Free Radical Biology and Medicine
Publisher
Elsevier BV
Published
2018-01
Volume
114
Pages
110-121
ISSN
0891-5849 (ISSN-L)
OpenAlex
W2752766390
Cited by
76
References
38
FWCI
2.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exosomal biomarkers in Down syndrome and Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.freeradbiomed.2017.08.028
The paper
Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A.-C. (2018). Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2017.08.028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.